| Business Summary | | Haemonetics
Corporation
is
engaged
in
the
manufacture
of
automated
systems
for
the
collection,
processing
and
surgical
salvage
of
blood.
The
Company
manages
its
business
on
the
basis
of
one
operating
segment-
the
design,
manufacture
and
marketing
of
automated
blood
processing
systems.
Haemonetics'
products
address
five
important
therapeutic
markets
for
blood
and
blood
components:
surgical
blood
salvage,
automated
plasma
collection,
automated
platelet
collection,
automated
red
cell
collection
and
cell
processing.
Haemonetics'
blood
processing
systems
consist
of
proprietary
disposable
sets
driven
by
specialized
equipment. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | HAE
is
engaged
in
the
design,
manufacture,
and
worldwide
marketing
of
automated
systems
for
the
collection,
processing
and
surgical
salvage
of
blood.
For
the
three
months
ended
6/30/01,
revenues
rose
8%
to
$75.8
million.
Net
income
before
acct.
chg.
rose
23%
to
$7.6
million.
Revenues
reflect
increased
red
cell,
plasma,
and
surgical
product
line
sales.
Net
income
also
benefited
from
increased
gross
profit
margins
and
the
adoption
of
the
FAS
142
accounting
change. | More
from
Market Guide: Significant
Developments |
| | | | FY2001 Pay | |
| Stuart Burgess, 72 Chairman | -- | James Peterson, 58 Pres,
CEO, Vice Chairman | $916K | Ronald Ryan CFO, Sr. VP | 358K | Thomas Headley Exec.
VP - Worldwide R&D | 1.3M | Timothy Surgenor Exec.
VP - Bus. Dev., Advanced R&D, Worldwide Solutions Bus., and Quality Assurance | 319K | Dollar
amounts are as of 31-Mar-2001 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|